We need to talk about clonal diversity


Session type:

Mel Greaves1

1The Institute of Cancer Research, London, UK


Intraclonal genetic diversity in individual patients' cancer cells is predictive of drug resistance and poor outcome. A major challenge of cancer therapeutics is how to thwart the resilience of the evolutionary process. This session will address three key aspects of this topic:
  • How we can best measure diversity?
  • Does the degree of diversity predict outcome?
  • How can we tackle or bypass clonal diversity, therapeutically?